| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| ln Vitro |
SCL-1 (0.25-100 μM, 4 days) showed no significant cytotoxicity against MDA-MB231 cells[1]. SCL-1 (25 μM) exhibited moderate inhibitory activity against PD-1/PD-L1 binding, with an inhibition rate of 63%[2]. SCL-1 inhibited the proliferation of SCC3 and Jurkat cells, with IC50 values >50 μM for both[2].
|
|---|---|
| ln Vivo |
SCL-1 (25-100 mg/kg, face, 14 hot spots 10 times) inhibits tumor growth in MHC-dKO NOG tumors with humanized MDA-MB231 tumor burden[1]. SCL-1 (50 mg/kg, face, 14 hot spots 10 times) modulates tumor growth in MHC-dKO NOG tumors with humanized SCC-3 tumor burden[2].
|
| Animal Protocol |
Animal/Disease Models: MDA-MB231 tumor in a humanized MHC-double knockout NOG mice models[1]
Doses: 25, 50 and 100 mg/kg Route of Administration: Orally administered, 10 times over 14 days (days 1-5 and 8-12) Experimental Results: Inhibited tumor volume. Did not induce weight loss. Increased infiltrated CD4+ and CD8+ T-cell numbers inside tumors. Increased the frequency of CD19+ B cells that infiltrated tumors. Showed high level of lymphoid cell infiltration. Upregulated T cell-associated cytotoxic genes (GZMB, PRF1, and IFNB1), exhausted marker genes (PD-1, TIM3, and CD39), NK activation-associated genes (CD16 and NCR1), and T-cell attracting chemokine genes (CCL3 and CCL4). Downregulated CXCL12 gene expression. Upregulated tumor-specific long non-coding (lnc) RNAs. Animal/Disease Models: Humanized SCC-3 tumor-bearing MHC-dKO NOG mice[2] Doses: 50 mg/kg Route of Administration: Orally administered, 10 times over 14 days (days 1-5 and 8-12) Experimental Results: Promoted the engraftment of transplanted human PBMCs in the spleens. Increased the number of infiltrated CD45+ human PBMCs and CD4+ and CD8+ T cells inside the tumors. Had more foci of lymphoid cell infiltration with necrotic changes. Increased CD8+ T cells. Upregulated the expression of CXCL9 and CXCR3. Downregulated the expression levels of CCL22 and TIM3. |
| References |
| Molecular Formula |
C18H23F3N6O
|
|---|---|
| Molecular Weight |
396.41
|
| CAS # |
1061105-16-5
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~252.26 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.31 mM)(saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one)),clear solution.
For example, if 1 mL of working solution is to be prepared, you can Add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix thoroughly. Then add 50 μL of Tween-80 to the above system and mix thoroughly. Finally, add 450 μL of physiological saline to bring the volume to 1 mL. Preparation of physiological saline: Dissolve 0.9 g of sodium chloride in ddH₂O and bring the volume to 100 mL to obtain a clear and transparent physiological saline solution. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.31 mM)(saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one)),clear solution. For example, if 1 mL of working solution is to be prepared, you can Add 100 μL of 25.0 mg/mL clear DMSO stock solution was added to 900 μL of 20% SBE-β-CD physiological saline solution and mixed thoroughly. 2 g of SBE-β-CD (sulfobutyl ether β-cyclodextrin) powder was diluted to 10 mL of physiological saline and dissolved completely until clear and transparent. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.31 mM)(saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one)),clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5226 mL | 12.6132 mL | 25.2264 mL | |
| 5 mM | 0.5045 mL | 2.5226 mL | 5.0453 mL | |
| 10 mM | 0.2523 mL | 1.2613 mL | 2.5226 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
